Request Demo

Last update 08 May 2025

Ouabain

Last update 08 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

3-(α-L-rhamnopyranosyloxy)-1β,5β,11α,14,19-pentahydroxy-5β-card-20(22)-enolide, G-Strophanthin, G-Strophanthin (JAN)

+ [6]

Target

ATP1A1

Action

inhibitors

Mechanism

Sodium/potassium-transporting ATPase alpha-1 chain inhibitors

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Heart Failure

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC29H60O20

InChIKeyTYBARJRCFHUHSN-DMJRSANLSA-N

CAS Registry11018-89-6

View All Structures (2)

100 Clinical Results associated with Ouabain

100 Translational Medicine associated with Ouabain

100 Patents (Medical) associated with Ouabain

17,489

Literatures (Medical) associated with Ouabain

01 Jun 2025·Current Research in Neurobiology

Ouabain increases neuronal differentiation of hippocampal neural precursor cells

Article

Author: Scavone, Cristoforo ; Kawamoto, Elisa M ; de Sá Lima, Larissa ; Neto, João Agostinho M ; Port's, Natacha Medeiros S ; Kinoshita, Paula Fernanda ; Andreotti, Diana Zukas ; Leite, Jacqueline Alves ; Orellana, Ana Maria ; Cantanzaro, Arthur B

Image 1.

01 May 2025·Microchemical Journal

Sensitive detection of sodium channel-inhibiting marine toxins via real-time and label-free cytotoxicity assay

Author: Zhao, Xiaotong ; Xie, Jianwei ; Xu, Hua ; Wu, Xiaohan ; Li, Zhi ; Ma, Bo ; Yan, Ting

Marine biotoxins represent a class of highly toxic neurotoxins found within marine ecosystems, the majority of which exert their effects on ion channels.Notably, sodium (Na+) channel inhibitory marine biotoxins are recognized as the most toxic among these compounds, posing significant risks to both human and animal health.Current methodologies for the detection of Na+ channel inhibitory marine biotoxins are fraught with ethical and tech. limitations.Therefore, it is imperative to develop a high-throughput, high-sensitivity, and user-friendly detection method for these toxins.In this study, we established a cellular impedance sensing method for the detection of Na+ channel inhibitory marine biotoxins, based on an ion channel effect-oriented strategy.Veratridine, a Na+ channel activator, combined with ouabain, a Na+/K+-ATPase inhibitor, induce a sustained influx of Na+ ions into cells, which can lead to cell death.In contrast, Na+ channel inhibitory marine biotoxins exhibit antagonistic effects against veratridine and ouabain, thereby preventing the influx of Na+ ions into the cell and promoting cell survival.This method showed high sensitivity for detecting various paralytic shellfish toxins (PSTs), with the limit of detection reaching 0.03 ng/mL for saxitoxin (STX).Moreover, the assay enables the comparative assessment of the toxicity of different PSTs and facilitates the semi-quant. detection of PSTs in real samples including com. available seafood products and those from the Organization for the Prohibition of Chem. Weapons (OPCW) biotoxin exercises.This method may be extended for the detection of other sodium channel-modulating toxins, broadening its applicability in food safety testing and environmental monitoring.

16 Apr 2025·Journal of Agricultural and Food Chemistry

Knockdown of Oatp and Mdr Transporter Genes Enhances Cardenolide Toxicity to the Noncardenolide Feeder, Nilaparvata lugens

Article

Author: Du, Zhao ; He, Yueping ; Yao, Zhangyi ; Li, Zengxin ; Zhang, Meng ; Gbeinbo, Fiderikumo Livingstone ; Zhu, Guonian ; Qiao, Liya

Insect adaptation to toxic cardenolides has been a model system to study convergent evolution between plants and herbivores. It was hypothesized that Organic anion-transporting polypeptides (Oatps) and multidrug transporters (Mdrs) provide basal resistance against cardenolides in a nonadapted insect. However, there is still little evidence to support this hypothesis. A noncardenolide feeder and an important rice pest, Nilaparvata lugens, were used to test this hypothesis. Bioassays revealed that two representative cardenolides, ouabain, and digoxin, demonstrated significant toxicity against N. lugens. The suppression of the expression levels of six Oatp genes and three Mdr genes by the RNAi did not result in any significant lethal phenotype in N. lugens. However, the knockdown of certain Oatp and Mdr genes significantly enhances the oral toxicity of ouabain and digoxin to N. lugens. The findings of our study support that Oatps and Mdrs are key transporters in N. lugens protection against dietary cardenolides.

100 Deals associated with Ouabain

External Link

KEGG	Wiki	ATC	Drug Bank
D00112	Ouabain	C01AC01	DB01092

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Heart Failure	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASN2018	Not Applicable	Renal Cell Carcinoma	-	Ouabain	jbrjrhbeiq(qcdrzdgups) = yrxuhasvps fhibazbcir (qcgjudoogr )	-	23 Oct 2018
ASN2016	Not Applicable	Diabetic Nephropathies	-	Ouabain (Glucose 10mM)	nbqiqmlalw(vcjzqqzsxo) = mkrmcpumad bjzhfazuqc (eohvxckfqo, 4.1)	Positive	15 Nov 2016
				Ouabain 5nM	nbqiqmlalw(vcjzqqzsxo) = hfiwazjpcm bjzhfazuqc (eohvxckfqo, 1.3)
ASN2014	Not Applicable	Hypertension serum uric acid \| endogenous ouabain \| ATP-binding cassette B1 gene	222	Ouabain (ABCB1 rs1045642 genotype)	hdehwrnngl(mhejdwvurc) = kacbazcdxz afhgpubvad (rowswqbbgo )	-	11 Nov 2014
ASN2014	Not Applicable	Proteinuria ouabain	-	Rostafuroxin 100 µg/kg/day	(kzzywhycaw) = yfskynoxiw nabxxtnzeg (jkqmrdyylj ) View more	Positive	11 Nov 2014
				Ouabain	(kzzywhycaw) = lmogoqyuvk nabxxtnzeg (jkqmrdyylj ) View more
ASN2012	Not Applicable	Dysentery, Bacillary Stx2 \| Gb3 receptors \| Bax ... View more	-	Ouabain/Na,K-ATPase (Stx2)	xuydpcwlyn(myjchmbesp) = okhcsfiymu rhzgdhcqrb (ebleoydkpd ) View more	Positive	30 Oct 2012
				Ouabain	xuydpcwlyn(myjchmbesp) = xfqguaukah rhzgdhcqrb (ebleoydkpd ) View more
ASN2010	Not Applicable	Hypertension Na-K ATPase \| NHE-1	-	Ouabain	(jdaivkhwbs) = yqizveednj ldhshibzqj (bgnpixaxhr, 3.26)	Positive	16 Nov 2010
				Vehicle	(jdaivkhwbs) = ptxhkiokvh ldhshibzqj (bgnpixaxhr, 5.32)
ARVO2008	Not Applicable	-	-	Ouabain 30 nM	fnhlarnkmv(nriwzumngl) = ybbwrkzahi gxegisduqd (vdmoyvpssw )	-	01 May 2008
				Ouabain (Control)	fnhlarnkmv(nriwzumngl) = uihcibcqis gxegisduqd (vdmoyvpssw )
SFN2007	Not Applicable	Cerebellar Neoplasms	-	Ouabain	qilqfbnsbn(ddzmcsofvf) = owhnfbsxew ggjvczhffq (ufdvmogmvu, 1.7)	-	04 Nov 2007
ARVO2005	Not Applicable	Iris Pigment Epithelium Anomalies	-	Ouabain	wcwmiqqtsf(zmcpubsdys) = ouabain did enhance BKCa-channel activity without a change in single-channel amplitude shzdeaphnx (lhjqneqxyn )	-	01 May 2005

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Ouabain

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation